ARHGDIB

Across TCGA pan-cancer cohorts, ARHGDIB mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ARHGDIB data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ARHGDIB mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ARHGDIB expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, COAD, and LUAD are the cancer types where ARHGDIB mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	II,III,IV	0.913	0.639	.001	32	view →
COAD	DFS	Median	II,III,IV	0.879	1.000	.019	24	view →
LUAD	DFS	Quartile	III,IV	0.177	0.804	<.001	20	view →
HNSC	DFS	Median	II,III,IV	0.897	0.993	.005	12	view →
CCRCC	DFS	Median	II,III,IV	0.934	0.805	.023	3	view →
LSCC	DFS	Median	II,III,IV	0.566	0.816	.043	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ARHGDIB–PDAC (DFS)

Open the PDAC breakdown →